Idecabtagene vicleucel (Abecma) — Clinical FAQs

Question 1

What is Idecabtagene vicleucel FDA-approved to treat?

Accepted Answer

Idecabtagene vicleucel is FDA-approved for the following oncology indications: 1. Relapsed or refractory multiple myeloma in adults who have received at least 4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (FDA approved March 26, 2021; based on KarMMa) 2. Relapsed or refractory multiple myeloma in adults who have received 2–4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (FDA expanded approval June 2024; based on KarMMa-3).

Question 2

How does Idecabtagene vicleucel work (mechanism of action)?

Accepted Answer

Idecabtagene vicleucel (ide-cel) is an autologous BCMA-directed CAR-T cell product based on the bb2121 lentiviral construct, incorporating a single anti-BCMA scFv fused to 4-1BB costimulatory and CD3ζ signaling domains. BCMA is highly expressed on malignant plasma cells, making it an attractive target in multiple myeloma. Following lymphodepletion and reinfusion, ide-cel T cells expand, traffic to bone marrow, recognize BCMA on plasma cells, and execute perforin/granzyme-mediated cytotoxicity and ADCC-like mechanisms. The single scFv BCMA-binding domain (compared to the dual-nanobody design of cilta-cel) may result in differences in binding avidity and the CRS/neurotoxicity profile. Immune-mediated bystander killing and cytokine release contribute to both therapeutic efficacy and toxicity.

Question 3

How is Idecabtagene vicleucel administered?

Accepted Answer

Idecabtagene vicleucel is administered Intravenous (IV). Single IV infusion administered at a certified facility.

Question 4

What are the most common side effects of Idecabtagene vicleucel?

Accepted Answer

The most commonly reported side effects of Idecabtagene vicleucel (≥10% incidence) include: CRS (any grade ~84% in KarMMa), Pyrexia, Fatigue, Cytopenias (neutropenia, anemia, thrombocytopenia), Hypotension and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Idecabtagene vicleucel have a black box warning?

Accepted Answer

Yes. Idecabtagene vicleucel carries FDA black box warning(s) regarding: 1. Cytokine release syndrome (CRS): severe CRS reported; onset generally within first week post-infusion; manage with tocilizumab ± corticosteroids 2. Immune effector cell-associated neurotoxicity syndrome (ICANS): includes encephalopathy and other neurological toxicities 3. Prolonged cytopenias: may persist weeks after lymphodepletion and infusion 4. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) 5. Available only through the ABECMA REMS Program

Question 6

Is Idecabtagene vicleucel safe during pregnancy?

Accepted Answer

Idecabtagene vicleucel pregnancy safety: No adequate human data; presumed fetal harm. Effective contraception required for at least 6 months post-infusion. Breastfeeding not recommended during and for at least 6 months after therapy.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

idecabtagene vicleucel — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms